vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Spire Global, Inc. (SPIR). Click either name above to swap in a different company.
Spire Global, Inc. is the larger business by last-quarter revenue ($15.8M vs $15.0M, roughly 1.1× CHAMPIONS ONCOLOGY, INC.). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -176.6%, a 178.4% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -26.9%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-16.2M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs -32.6%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Spire Global, Inc. is a space-to-cloud data and analytics company that specializes in the tracking of global data sets powered by a large constellation of nanosatellites, such as the tracking of maritime, aviation and weather patterns.
CSBR vs SPIR — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $15.8M |
| Net Profit | $268.0K | $-28.0M |
| Gross Margin | 51.7% | 40.2% |
| Operating Margin | 1.2% | -164.1% |
| Net Margin | 1.8% | -176.6% |
| Revenue YoY | 11.5% | -26.9% |
| Net Profit YoY | -63.2% | 42.7% |
| EPS (diluted) | $0.02 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $15.8M | ||
| Q3 25 | $14.0M | $12.7M | ||
| Q2 25 | $12.4M | $19.2M | ||
| Q1 25 | $17.0M | $23.9M | ||
| Q4 24 | $13.5M | $21.7M | ||
| Q3 24 | $14.1M | $28.6M | ||
| Q2 24 | $14.0M | $25.4M | ||
| Q1 24 | $12.0M | $34.8M |
| Q4 25 | $268.0K | $-28.0M | ||
| Q3 25 | $-436.0K | $-19.7M | ||
| Q2 25 | $-1.8M | $119.6M | ||
| Q1 25 | $4.5M | $-20.7M | ||
| Q4 24 | $728.0K | $-48.8M | ||
| Q3 24 | $1.3M | $-12.5M | ||
| Q2 24 | $-109.0K | $-16.6M | ||
| Q1 24 | $-2.5M | $-25.5M |
| Q4 25 | 51.7% | 40.2% | ||
| Q3 25 | 42.9% | 36.6% | ||
| Q2 25 | 41.1% | 48.9% | ||
| Q1 25 | 61.2% | 36.8% | ||
| Q4 24 | 44.9% | 32.4% | ||
| Q3 24 | 49.7% | 44.5% | ||
| Q2 24 | 48.2% | 43.0% | ||
| Q1 24 | 34.7% | 26.5% |
| Q4 25 | 1.2% | -164.1% | ||
| Q3 25 | -3.8% | -166.1% | ||
| Q2 25 | -16.2% | -122.7% | ||
| Q1 25 | 26.4% | -106.5% | ||
| Q4 24 | 5.4% | -144.1% | ||
| Q3 24 | 9.5% | -48.0% | ||
| Q2 24 | -1.9% | -48.6% | ||
| Q1 24 | -21.4% | -34.4% |
| Q4 25 | 1.8% | -176.6% | ||
| Q3 25 | -3.1% | -155.3% | ||
| Q2 25 | -14.9% | 623.4% | ||
| Q1 25 | 26.4% | -86.5% | ||
| Q4 24 | 5.4% | -225.2% | ||
| Q3 24 | 9.3% | -43.7% | ||
| Q2 24 | -0.8% | -65.2% | ||
| Q1 24 | -21.1% | -73.3% |
| Q4 25 | $0.02 | $-0.85 | ||
| Q3 25 | $-0.03 | $-0.61 | ||
| Q2 25 | $-0.12 | $3.72 | ||
| Q1 25 | $0.31 | $-0.77 | ||
| Q4 24 | $0.05 | $-1.93 | ||
| Q3 24 | $0.09 | $-0.50 | ||
| Q2 24 | $-0.01 | $-0.68 | ||
| Q1 24 | $-0.19 | $-1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $81.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $112.9M |
| Total Assets | $30.2M | $211.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $81.8M | ||
| Q3 25 | $10.3M | $96.8M | ||
| Q2 25 | $9.8M | $117.6M | ||
| Q1 25 | $3.2M | $35.9M | ||
| Q4 24 | $2.8M | $19.2M | ||
| Q3 24 | $2.9M | $36.6M | ||
| Q2 24 | $2.6M | $45.8M | ||
| Q1 24 | $4.5M | $63.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $103.7M | ||
| Q4 24 | — | $103.1M | ||
| Q3 24 | — | $4.9M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $123.1M |
| Q4 25 | $4.2M | $112.9M | ||
| Q3 25 | $3.5M | $133.1M | ||
| Q2 25 | $3.8M | $149.2M | ||
| Q1 25 | $5.5M | $3.7M | ||
| Q4 24 | $681.0K | $-11.7M | ||
| Q3 24 | $-332.0K | $30.8M | ||
| Q2 24 | $-1.9M | $40.3M | ||
| Q1 24 | $-2.1M | $52.5M |
| Q4 25 | $30.2M | $211.0M | ||
| Q3 25 | $30.5M | $224.3M | ||
| Q2 25 | $32.3M | $239.5M | ||
| Q1 25 | $30.6M | $208.8M | ||
| Q4 24 | $25.2M | $193.6M | ||
| Q3 24 | $24.9M | $224.2M | ||
| Q2 24 | $26.1M | $230.8M | ||
| Q1 24 | $26.8M | $252.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 27.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 2.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-4.3M |
| Free Cash FlowOCF − Capex | $-2.0M | $-16.2M |
| FCF MarginFCF / Revenue | -13.1% | -102.1% |
| Capex IntensityCapex / Revenue | 1.6% | 75.1% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-92.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-4.3M | ||
| Q3 25 | $600.0K | $-12.0M | ||
| Q2 25 | $6.9M | $-35.1M | ||
| Q1 25 | $490.0K | $-8.4M | ||
| Q4 24 | $-283.0K | $-19.2M | ||
| Q3 24 | $311.0K | $14.0M | ||
| Q2 24 | $-1.8M | $-4.4M | ||
| Q1 24 | $-919.0K | $-8.8M |
| Q4 25 | $-2.0M | $-16.2M | ||
| Q3 25 | $554.0K | $-20.4M | ||
| Q2 25 | $6.6M | $-38.7M | ||
| Q1 25 | $448.0K | $-17.3M | ||
| Q4 24 | $-377.0K | $-24.3M | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | $-1.8M | $-9.9M | ||
| Q1 24 | $-1.0M | $-15.9M |
| Q4 25 | -13.1% | -102.1% | ||
| Q3 25 | 4.0% | -161.3% | ||
| Q2 25 | 53.5% | -201.7% | ||
| Q1 25 | 2.6% | -72.6% | ||
| Q4 24 | -2.8% | -112.2% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | -13.0% | -39.0% | ||
| Q1 24 | -8.4% | -45.7% |
| Q4 25 | 1.6% | 75.1% | ||
| Q3 25 | 0.3% | 66.2% | ||
| Q2 25 | 2.0% | 18.8% | ||
| Q1 25 | 0.2% | 37.3% | ||
| Q4 24 | 0.7% | 23.5% | ||
| Q3 24 | 0.0% | 31.2% | ||
| Q2 24 | 0.0% | 21.8% | ||
| Q1 24 | 0.8% | 20.3% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.29× | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
SPIR
Segment breakdown not available.
